Shares Outstanding (Quarterly) Chart

View Shares Outstanding (Quarterly) for ORGO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shares Outstanding (Quarterly) Chart
Start Trial

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 2016. Start Trial.
Date Value
June 30, 2026 128.67M
March 31, 2026 128.67M
December 31, 2025 126.95M
September 30, 2025 126.91M
June 30, 2025 126.85M
March 31, 2025 126.85M
December 31, 2024 125.73M
September 30, 2024 132.58M
June 30, 2024 132.57M
March 31, 2024 132.54M
December 31, 2023 131.32M
September 30, 2023 131.31M
June 30, 2023 131.31M
March 31, 2023 131.23M
December 31, 2022 130.92M
September 30, 2022 130.92M
June 30, 2022 130.89M
March 31, 2022 128.89M
December 31, 2021 128.68M
September 30, 2021 128.64M
Date Value
June 30, 2021 128.28M
March 31, 2021 128.10M
December 31, 2020 127.73M
September 30, 2020 107.46M
June 30, 2020 105.42M
March 31, 2020 105.36M
December 31, 2019 104.87M
September 30, 2019 94.74M
June 30, 2019 91.34M
March 31, 2019 91.32M
December 31, 2018 91.26M
September 30, 2018 36.81M
June 30, 2018 9.876M
March 31, 2018 9.791M
December 31, 2017 9.683M
September 30, 2017 9.559M
June 30, 2017 9.278M
March 31, 2017 9.259M
December 31, 2016 9.239M
September 30, 2016 38.62M

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
cbdMD, Inc. 11.12M
Guardian Pharmacy Services, Inc. 63.33M
ACADIA Pharmaceuticals, Inc. 172.13M
Agenus, Inc. 42.62M
Alnylam Pharmaceuticals, Inc. 133.73M